In-Silico and In-Vivo Evaluation of Luteolin and Imeglimin as Novel Therapeutic Agents in Reserpine-Induced Parkinsons Disease in Rats Neuroprotective effects of luteolin and Imeglimin in reserpine-induced Parkinsons disease in rats
Iranian Journal of Pharmaceutical Sciences,
Vol. 22 No. 1 (2026),
26 Bahman 2026
,
Page 223-235
https://doi.org/10.22037/ijps.v22i1.50486
Abstract
Parkinson's disease (PD) is the second most prevalent late-life movement disorder, characterized as a hypokinetic condition involving selective and extensive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) of the striatum. This study investigated the neuroprotective effects of luteolin and imeglimin against reserpine-induced PD in rats, focusing on the dopamine transporter protein (DAT), α-synuclein aggregation, and proinflammatory cytokines using both in silico and in vivo approaches. In- silico molecular docking studies were followed by in vivo experiments. PD was induced in rats by administration of reserpine (1 mg/kg, s.c.) every other day for 3 days. Pretreatment with luteolin (50 mg/kg, p.o.) and imeglimin (100 mg/kg, p.o.) was given for 5 days. Behavioral assessments (orofacial dyskinesia, catalepsy, and rotarod) were performed on day 5, followed by biochemical and histopathological evaluations. Parameters measured included oxidative stress markers (CAT, GSH, SOD, and LPO), neurotransmitters (dopamine and nitric oxide), proinflammatory cytokines (TNF-α and IL-1β), and α-synuclein expression.
Reserpine-treated rats exhibited increased catalepsy duration, orofacial dyskinesia (tongue protrusions, vacuous chewing), and impaired motor coordination. Biochemical analysis showed reduced antioxidant levels (CAT, GSH, SOD), reduced dopamine levels, and elevated LPO, TNF-α, IL-1β, and α-synuclein. Combined treatment with luteolin and imeglimin significantly mitigated these behavioral and biochemical alterations—improving locomotor activity, reducing dyskinesia, and normalizing antioxidant and inflammatory markers. Dopamine levels were restored, and α-synuclein aggregation was notably reduced. Histopathology confirmed dopaminergic neuronal preservation and reduced Lewy body formation in the treatment group. These findings suggested that luteolin and imeglimin, particularly in combination, offer neuroprotective effects in PD by reducing oxidative stress, inflammation, and α-synuclein aggregation, thereby preserving dopaminergic neurons and brain function.
- α-Synuclein
- DAT
- Imeglimin
- Luteolin
- Parkinsons disease
- Neuroinflammation
How to Cite
References
1. Balakris hnan R, Azam S, Cho DY, Su-Kim I, Choi DK. Natural phytochemicals novel therapeutic strategies to prevent and treat Parkinson's disease: current knowledge and future perspectives. Oxid Med Cell Longev (2021): 6680935.
2. Bonnet AM, Houeto JL. Pathophysiology of Parkinson's disease. Biomed Pharmacother (1999) 53(3):117-121.
3. Chagraoui A, Boulain M, Juvin L, Anouar Y, Barrière G, De Deurwaerdère P. L-DOPA in Parkinson's disease: Looking at the "false" neurotransmitters. Int J Mol Sci (2019); 21(1):294.
4. Li Y, Lou N, Liu X, Zhuang X, Chen S. Exploring new mechanisms of imeglimin in diabetes treatment: amelioration of mitochondrial dysfunction. Biomed Pharmacother (2024); 175:116755.
5. Nade VS, Ahire VA, Nikam VB, Kawale LA, Bombale PV, Patil DA, et al. Unlocking the power of phytochemicals in Parkinson's disease: bridging insights to future therapeutics. world j pharm sci (2024); 172:115195.
6. Jia Y, Liu T, Yu X, Zhang X, Wang K. Herbal medicines for Parkinson's disease: a systematic review of randomized controlled trials. Front Aging Neurosci (2012); 4:18.
7. Wang HR, Pei SY, Fan DX, Liu YH, Pan XF, Song FX, et al. Luteolin protects PC-12 cells against Aβ25-35-induced apoptosis through the ER/ERK/MAPK pathway. Evid Based Complement Alternat Med (2020): 2861978.
8. Sternberg Z, Chadha K, Lieberman A, Drake A, Hojnacki D, Weinstock-Guttman B, et al. Immunomodulatory responses of peripheral blood mononuclear cells from multiple sclerosis patients upon in vitro incubation with luteolin. J Neuroinflammation (2009); 6:28.
9. Jayawickreme DK, Ekwosi C, Anand A, Andres-Mach M, Wlaź P, Socała K, et al. Luteolin for neurodegenerative diseases: a review. Pharmacol Rep (2024); 76(4):644-68.
10. Parvathaneni V, Kulkarni NS, Muth A, Gupta V. Drug repurposing: a promising tool to accelerate drug discovery. Drug Discov Today (2019); 24(10):2076-85.
11. Pirags V, Lebovitz H, Fouqueray P. Imeglimin, a novel glimin oral antidiabetic, exhibits good efficacy and safety in type 2 diabetes. Diabetes Obes Metab (2012); 14(9):852-8.
12. Burger ME, Alves A, Callegari L, Athayde FR, Nogueira CW, Zeni G, et al. Ebselen attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum. Prog Neuropsychopharmacol Biol Psychiatry (2003); 27(1):135-40.
13. Kulkarni OS, Joshi SK, Thatte UM, Bhalerao S. Evaluation of toxicological and antioxidant potential of Nardostachys jatamansi in reversing haloperidol-induced catalepsy in rats. Indian J Physiol Pharmacol (2019); 63(3):236-41.
14. Seibenhener ML, Wooten MC. Use of the open field maze to measure locomotor and anxiety-like behavior in mice. J Vis Exp (2015); (96):e52434.
15. Luck H. Methods of enzymatic analysis. Academic Press, New York (1971): 885-93.
16. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys (1959); 82(1):70-7.
17. Wills ED. Mechanism of lipid peroxide formation in animal tissues. Biochem J (1966); 99(3):667-76.
18. Kono Y. Generation of superoxide radical during autooxidation of hydroxylamine and an assay for superoxide dismutase. Arch Biochem Biophys (1978); 186(1):189-95.
19. Gopi C, Sastry VG, Dhanaraju MD. Effect of novel phenothiazine derivatives on brain dopamine in Wistar rats. Beni Suef Univ J Basic Appl Sci (2019); 8(1):7.
20. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem (1982); 126(1):131-8.
21. Murakami H, Shiraishi T, Umehara T, Omoto S, Iguchi Y. Recent Advances in Drug Therapy for Parkinson's Disease. Internal Med (2023); 62(1):33-42.
22. Schonecker M. A strange syndrome in the oral area with application of chlorpromazine. Nervenarzt (1957); 28(12):526-8.
23. Patil RA. Piper nigrum mitigates reserpine-induced orofacial dyskinesia in Wistar rats. EC Pharmacol Toxicol (2022); 10:1-13.
24. Nade VS, Mardhekar VY, Bhoye UR, Kawale LA. Neuroprotective effect of linagliptin and celiprolol in reserpine-induced orofacial dyskinesia and rotenone neurodegeneration in rats. Int J Curr Pharm Res (2020); 12(4):63-71.
25. Naidu PS, Singh A, Kulkarni SK. Effect of Withania somnifera root extract on reserpine- induced orofacial dyskinesia and cognitive dysfunction. Phytother Res (2006); 20(2):140-6.
26. Zhang J, Liu X, Lei X, Wang L, Guo L, Zhao G, et al. Discovery and synthesis of novel luteolin derivatives as dopamine transporter agonists. Bioorg Med Chem (2010); 18(22):7842-8.
- Abstract Viewed: 20 times
- IJPS_Volume22_Issue1_Pages223-235 Downloaded: 12 times